Normal blood cell production -haematopoiesis -is crucial for the maintenance of health. 1 Haematopoiesis is initiated through rare populations of haematopoietic stem (HSC) and progenitor (HPC) cells that give rise to all blood-forming elements: HSCs/HPCs are found in the bone marrow of adults, where they are produced and nurtured.
Enhanced Mobilisation of Haematopoietic Stem and Progenitor Cells by AMD3100
G-CSF is the gold standard for mobilisation of HSCs/HPCs for use in autologous and allogeneic HSC transplantation. 9, 10 However, not all patients respond well to the mobilising effects of G-CSF. Thus, additional agents are needed for mobilisation of HSCs/HPCs. In this context, AMD3100 has been of practical value for mobilising HSCs/HPCs in man, [11] [12] [13] [14] [15] [16] [17] mice, 11 dogs 18 and monkeys, 19 especially in synergy with G-CSF. Although the human studies the authors were involved in were published first, 12-14 the initial proof of principle that AMD3100 mobilises HSCs and HPCs was performed in mice, where we demonstrated that mobilisation by AMD3100 was rapid and maximal within one hour, and that a single dose of AMD3100 greatly enhanced mobilisation of HSCs/HPCs induced by G-CSF. 11 While it took one hour to maximally mobilise HSCs/HPCs to the blood of mice, it took six to nine hours to maximally mobilise human CD34 + cells (which contain mobilises an earlier subset of HSCs than G-CSF, 11, 19 and that cells mobilised with AMD3100, or the combination of AMD3100 plus G-CSF, are a higher-quality HSC than those mobilised by G-CSF. 11 This belief is supported by evaluation of the genomics of mobilised cells. 20 Structural analogues of AMD3100 are under investigation as nextgeneration mobilisers based on their ability to inhibit binding of SDF-1/CXCL12 to CXCR4. 21 Chemokines macrophage inflammatory protein (MIP)-1α/CCL3 22 and GRO-β/CXCL2 [23] [24] [25] have HSC/HPC-mobilising capability; both synergise with G-CSF in this capacity. Greatest mobilisation may entail combined effects of AMD3100 and G-CSF with either MIP-1α/CCL3 or GRO-β/ CXCL2. Based on the minimal mobilising activity of MIP-1α/CCL3 alone in phase I clinical trials, 26 it is possible that GRO-β/CXCL2 may be a preferred reagent in double or triple combination treatment. Effects of GRO-β/CXCL2 are mediated by neutrophil-derived marrow matrix metalloproteinase 9, and GRO-β/CXCL2 mobilises early HSC characterised by enhanced homing and engrafting capabilities. [23] [24] [25] Modulating the Interaction of Stromal-cell-derived Factor-1/CXCL12 and its Receptor, CXCR4, for Enhanced Mobilisation, Homing and Engraftment of Haematopoietic Stem Cells There is evidence that HSCs may not home with absolute efficiency and that this homing can be enhanced. 28 Inhibition of CD26/DPPIV has shown efficacy in enhancing homing and engraftment of mouse HSCs into lethally irradiated mice. 28 CD26 is a cell-surface dipeptidase expressed widely throughout the body. 29 It is a 110kDA glycoprotein with a small cytoplasmic region, a transmembrane section and an extracellular section containing the enzymatic activity. 29 The dipeptidylpeptidase region of CD26 cleaves the N-terminal dipeptide from various substrates, including chemokines, at the penultimate proline or alanine residue. [29] [30] [31] The action of CD26 on SDF-1/CXCL12 has biological consequences regarding HSC chemotaxis. 32 Immature HPCs/HSCs from human CB and mouse bone marrow express CD26 on their surface. 28 32 This led us to evaluate inhibition of CD26 for enhanced homing/engraftment of mouse BM HSCs. 28 Pre-treating donor HSCs/HPCs for transplant in a congenic mouse assay with Diprotin A or Val-Pyr for short periods before transplant significantly increased short-term homing, long-term engraftment, noncompetitive and competitive repopulation of the donor cells and secondary repopulation of donor cells, the last being a measure of the self-renewal ability of donor HSCs. 28 Donor HSC from CD26-/-mice were also found to have increased homing and engraftment. 28 These effects have since been reproduced by at least two independent laboratories. The first showed that inhibition of CD26 enhanced engraftment of limited numbers of virally transduced HSC expressing a recombinant allogeneic MHC class I molecule. 36 The second group demonstrated that CD26 inhibition significantly increased homing and engraftment in the context of non-ablative, allogeneic in utero HSC transplantation. 37 To assess clinical feasibility, we evaluated the effect of short pre- There is evidence that haematopoietic stem cells may not home with absolute efficiency and that this homing can be enhanced.
Modulating the Interaction of Stromal-cell-derived Factor-1/CXCL12 and its Receptor, CXCR4 independent laboratories published at the same time confirmed the enhancing effects of inhibition of CD26 on engraftment of human HSCs. 38, 39 One study with CB cells suggested that CD34-CD26 + accessory cells negatively affect engraftment of the repopulating HSCs, and that inhibiting these cells as well as the CD34+CD26+ cells leads to dramatic increases in cell engraftment. 38 The other evaluated engraftment of G-CSF mobilised CD34 + cells. 39 However, these cells expressed little or no CD26, so the investigators found that engraftment was enhanced by pre-treating the recipient NOD/SCID mice rather than the donor cells. 39 We also found that in vivo treatment of recipient mice with Diprotin A enhances primary competitive and secondary non-competitive repopulating capacity of untreated congenic mouse bone marrow donor HSCs. 22 
